Amgen reports Sjogren Phase 3 win. Cantor lifts Amgen stock target to USD 440.00

Published on 10/15/2026 at 10:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock costs EUR 385.38 on October 15, 2026, 0.57 percent above the Xetra close. Q2 revenue rose 9.50 percent to USD 10.05 billion.

Clinical pipeline and earnings dates

Amgen's OASIZ 301 study met its primary endpoint at week 48 on September 22, 2026.
Second-quarter revenue reached USD 10.05 billion, up 9.50 percent year over year.
Amgen stock trades at EUR 385.38 at 10:07 a.m. CEST at Lang & Schwarz on October 15, 2026, 0.57 percent above the Xetra close of October 14, 2026.
Nasdaq lists November 3, 2026, as the expected date for third-quarter results.

Aquarellmalerei eines kalifornischen Firmencampus mit Glasgebäuden, Palmen und sanften Hügeln im Hintergrund — Amgen Inc. (ISIN US0311621009) wird hier als Aquarell-Landschaft mit kalifornischem Biotech-Campus dargestellt, Illustration mit AI erstellt.

Amgen (ISIN US0311621009) was trading at EUR 385.38 at Lang & Schwarz on October 15, 2026, at 10:07 a.m. CEST, up 0.57 percent versus the Xetra close of October 14, 2026 at EUR 383.20. The company had reported a Phase 3 win for its dazodalibep program, while Cantor Fitzgerald raised its price target from USD 400.00 to USD 440.00 on October 8, 2026.

Amgen advances its pipeline

Amgen said on September 22, 2026, that the OASIZ 301 study of dazodalibep met its primary endpoint at week 48 in patients with moderate-to-severe systemic Sjogren disease. The company said improvements in disease activity appeared by week 4 and continued through week 48.

The result matters because the trial targets a condition with no FDA-approved systemic medicines, according to the company release. Amgen also said the follow-up OASIZ 303 study is expected to complete in the fourth quarter of 2026, giving the pipeline story a second dated milestone.

What does the target increase signal?

Investing.com reported on October 8, 2026, that Cantor Fitzgerald lifted its Amgen target to USD 440.00 from USD 400.00 while keeping a Neutral rating. The firm tied its view to commercial execution and the need for further pipeline updates.

Amgen's second-quarter 2026 revenue was USD 10.05 billion, up 9.50 percent from the same quarter a year earlier, according to MarketBeat. The same report said quarterly earnings per share were USD 6.29, above the USD 5.62 consensus estimate, although the analyst consensus remained Hold with an average target of USD 387.93.

Key dates for the next report

Nasdaq lists November 3, 2026, as the expected date for Amgen's third-quarter 2026 earnings announcement after the market close. The report is expected to cover the quarter ended September 2026, making commercial growth and clinical progress the key points for the next update.

Stock holds above the Xetra close

Amgen's market capitalization was USD 230.0 billion as of October 15, 2026, while its US listing is on the Nasdaq under ticker AMGN. The company is part of the Nasdaq-100, and the latest price sits below Cantor Fitzgerald's USD 440.00 target.

Amgen was trading at EUR 385.38 at Lang & Schwarz on October 15, 2026, at 10:07 a.m. CEST, 0.57 percent above the Xetra close of October 14, 2026 at EUR 383.20. The further course of trading is shown by the continuously updated real-time quote of Amgen stock.